News

Understanding Virbac’s Share Structure and Voting Rights Update

Understanding Virbac’s Share Structure and Voting Rights Update

Overview of Virbac's Share Structure

Virbac, a global leader in animal health, is dedicated to enhancing the well-being of various animal species through innovative health solutions. As part of its commitment to shareholders and stakeholders, Virbac regularly discloses updated information on its share structure and voting rights, ensuring transparency in its corporate governance practices.

Key Information for Shareholders

According to the recent declaration, as of November 30, 2025, Virbac recorded a total of 8,390,660 shares that represent its share capital. These shares correspond to a gross total of 12,704,542 voting rights. However, when accounting for shares without voting rights, the net total of voting rights is slightly less, standing at 12,691,706. This distinction is crucial for investors and stakeholders who are keen on understanding their voting influence at company meetings.

Importance of Voting Rights

Voting rights are a significant aspect of corporate structure, as they empower shareholders to influence company decisions, including the election of board members and approval of major corporate actions. In the case of Virbac, maintaining a healthy ratio of voting rights to shares underlines the company's dedication to shareholder engagement, reflecting a balanced power structure.

Virbac's Market Presence

Listed on Euronext Paris under the ticker Paris:VIRP, Virbac continues to offer a diverse range of products and solutions aimed at animal health. The company's presence on a prominent stock exchange not only enhances its visibility but also allows investors to engage more actively with the company’s developments.

Contact Information for Stakeholders

Investors and stakeholders can easily reach out for inquiries or further information. Corporate Finance at Virbac can be contacted at tel. 33 4 92 08 71 32 or through the email address finances@virbac.com. For more detailed insights, potential investors can explore Virbac’s official website at www.virbac.com.

Conclusion

In conclusion, the information regarding the number of shares and voting rights is vital for all stakeholders involved with Virbac. As the company continues to shape the future of animal health through innovative solutions and responsible corporate governance, understanding these metrics helps ensure that investors are well-informed. With an impressive commitment to animal health and transparent operations, Virbac remains a pivotal player in its industry.

Frequently Asked Questions

What is the total number of shares for Virbac?

The total number of shares for Virbac is 8,390,660.

How many voting rights does each share confer?

Each share confers voting rights, resulting in a gross total of 12,704,542 voting rights, adjusting for shares without voting rights.

Where is Virbac listed?

Virbac is listed on Euronext Paris under the ticker Paris:VIRP.

How can shareholders contact Virbac for inquiries?

Shareholders can contact Virbac via phone at tel. 33 4 92 08 71 32 or email finances@virbac.com.

What sector does Virbac operate in?

Virbac operates in the animal health sector, providing a range of health solutions for animals.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking High Performance: WorkBoard's New AI Enhancements

Updated Category News Views 101

Back in 2024, WorkBoard turned heads with its ambitious AI enhancements designed to overhaul strategy execution. You remember how organizations were struggling to keep their objectives on track? Well, that was the backdrop when WorkBoard stepped in, hoping to redefine the game. AI Capabilities: A Game Changer or Just Hype? At the Accelerate conference that year, buzz...

Continue Reading
Strengthening Leadership for Enhanced AI-Powered Aesthetics

Updated Category News Views 380

Cloud Clinic Enhances Leadership for Future Growth Cloud Clinic, an innovative healthcare technology platform, is embarking on a significant journey to expand its leadership team. This decision comes as the company aims to accelerate its growth and improve patient care across the nation. Strategic Leadership Appointments Leading the charge is John Sandberg, the visionary...

Continue Reading
HKBU Advances Wastewater Treatment with Innovative Technology

Updated Category News Views 220

Transforming Wastewater Treatment with Innovative Membranes Recent advancements by a dedicated research team from Hong Kong Baptist University (HKBU) have led to the creation of a groundbreaking catalytic membrane. This novel technology significantly enhances the effectiveness of wastewater treatment processes using advanced oxidation methods. Such innovations are crucial...

Continue Reading
CleanCore Solutions Successfully Completes Significant Funding Round

Updated Category News Views 255

CleanCore Solutions Completes Major Private Placement Today, CleanCore Solutions, Inc. (NYSE American: ZONE) announced the successful closing of a significant private investment in public equity (PIPE) financing. This funding has raised an impressive $175,000,420, a noteworthy achievement prior to deducting any agent fees or related expenses, utilizing a mix of cash and...

Continue Reading
Understanding Western Alliance Bancorporation's Legal Challenges

Updated Category News Views 181

Background on Western Alliance Bancorporation Western Alliance Bancorporation is a prominent bank holding company, primarily engaged in various banking services. Recently, the firm has come under scrutiny due to allegations concerning misleading business information exchanged with investors. This situation compels attention from current and potential investors alike,...

Continue Reading